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$10–$35, respectively. In a group-based delivery sce-
nario, vaccination was cost-saving compared to no vac-
cine and remained so if the vaccine cost was $28/dose
(the break-even price). In the individual-based scenario,
vaccination was cost-saving if the cost was $5/dose. In
this scenario, nearly half of lost productivity in the vac-
cine group was attributable to visits to administer the
vaccine, which overshadowed the relatively modest sav-
ings in ILI-associated costs averted. CONCLUSIONS:
Routine use of intranasal influenza vaccine among healthy
children may be cost-effective and may be maximized by
using group-based vaccination approaches.
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INTRODUCTION: The American College of Chest Phy-
sicians/Society of Critical Care Medicine Consensus Con-
ference defined severe sepsis as a systemic inflammatory
syndrome in response to infection associated with acute
organ dysfunction. Often, septicemia codes have been
used in administrative datasets as a proxy for severe sep-
sis. However, these entities are not necessarily the same
and one study found large differences in mortality be-
tween septicemia patients with and without severe sepsis
(54% vs. 15%). We explored the accuracy of septicemia
codes as identifiers of severe sepsis. METHODS: We se-
lected all patients with septicemia or severe sepsis (bacte-
rial or fungal infection plus acute organ failure) in the
1996 Florida hospital discharge database (n  1,936,479)
and compared differences between the groups. Septicemia
was defined using the ICD-9-CM code 038.xxx. We de-
fined severe sepsis using a more sophisticated strategy pre-
viously validated against prospective clinical and physio-
logic criteria. RESULTS: We found 58,598 patients with
severe sepsis, 53.4% of whom were in the intensive care
unit (ICU). We found 57,875 patients with septicemia,
30.9% of whom were in the ICU. Patients with severe
sepsis had a higher mortality (24.1% vs. 18.0%, p 
0.001) and higher hospital costs ($20.4k vs. $14.4k, p 
0.001). For patients with an ICU stay, hospital mortality
was 14.4% among the 7,927 septicemia cases without se-
vere sepsis, 23.5% among the 21,655 cases of severe sep-
sis without septicemia and 42.1% among the 9,970 cases
of severe sepsis with septicemia. The mean hospital cost in
these three groups was $18,381, $24,396, and $33,470
respectively. Of all selected patients (n  99,126), 17.5%
met criteria for both septicemia and severe sepsis. The
sensitivity and positive predictive values of septicemia
codes as predictors of severe sepsis are 29.6% and 30.0%
respectively. CONCLUSIONS: Septicemia codes are not
accurate for identifying patients with severe sepsis.
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BACKGROUND: The Medi-Cal program in California
added second-generation antipsychotic medications to its
formulary in October 1997. OBJECTIVE: Investigate the
impact of the formulary expansion on patient outcomes
for olanzapine and risperidone patients before and after
the formulary expansion. STUDY POPULATION: The
study population consisted of 13,106 olanzapine and
15,718 risperidone ambulatory patients from the 100%
Medi-Cal dataset, who were classified into 3 groups.
New: no previous antipsychotic drug therapy history. Re-
starters: re-started antipsychotic drug therapy while not
on active therapy. Switcher: who switched to one of these
products while on active drug therapy. METHODS:
Models of one-year treatment costs were estimated using
both OLS regression and propensity score methods.
Models included over 85 covariates for patient demo-
graphics, prior use of services, prior antipsychotic drug
profile and diagnostic profile. Separate models were esti-
mated for the 3 patient populations. Outcomes include
total costs over one year broken down into component
costs and days of uninterrupted drug therapy achieved af-
ter re-starting therapy. RESULTS: The formulary expan-
sion immediately increased the number of new, switcher,
restarter patients starting therapy with risperidone and
olanzapine. Olanzapine patients were more likely to be
male, between the ages of 30 and 60, urban residents and
AFDC recipients. For restarters and switchers, Olanza-
pine patients also appear to be more compliant with their
prior antipsychotic drug regimen. Once these differences
were accounted for, Risperidone and olanzapine patients
exhibited similar treatment cost profiles in the post-
expansion period. CONCLUSIONS: More research is
needed to determine if the formulary expansion reduced
the cost of treating patients with schizophrenia. Further-
more, future comparison across drugs must take into ac-
count potential treatment selection bias and formulary
expansion effects on the decision to start drug therapy.
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OBJECTIVE: Antipsychotic therapies are often evaluated
on the basis of clinical endpoints (BPRS, PANSS) and
measures of direct cost. However, schizophrenia patients
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pose a substantial burden in terms of indirect costs, much
of which is attributable to loss of employment. We
present a new approach to assess the cost-effectiveness of
Risperidone Vs Haloperidol, using employability as an
outcome measure. METHODS: A decision analytic cost-
effectiveness model was developed to compare the two
treatments over a one-year period including all direct
medical costs and the number of employable persons as a
measure of effectiveness. A measure of executive func-
tioning, the Wisconsin Card Sort Test (WCST), was used
as an intermediate endpoint from which employability
was modeled. A Monte-Carlo procedure, using WCST
sampling distributions from clinical trials, simulated the
WCST score distribution for a cohort of 10,000 patients.
A clinically stable patient, with a Positive and Negative
Syndrome Scale (PANSS) score increase of at least 20%
and a WCST-Category score of 3.5 was assumed to be
employable. Sensitivity analysis was performed for key
values. RESULTS: The base case per-patient cost of Ris-
peridone and Haloperidol was $5,967 and $4,622 re-
spectively and the number of employable persons was
3,258 (32.58%) and 2,517 (25.17%) respectively. Ris-
peridone remained cost increasing and had higher num-
ber of employable persons over all the ranges used in the
sensitivity analysis. The base case incremental cost-effec-
tiveness ratio for Risperidone was $14,507 for each addi-
tional employable person. The incremental CE ratio
ranged from a high of $100,000 to a low of $3,000 per
employable persons when the rates of clinical stability for
Risperidone and Haloperidol therapy were varied. CON-
CLUSION: Gains from earning rates for employed
schizophrenics, savings in informal caregiver costs and
other intangible positive effects could justify an incre-
mental cost of $14,507 for each additional employable
person prescribed Risperidone.
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OBJECTIVE: To determine whether persons with deficit
syndrome exhibit lower quality of life than do their coun-
terparts. METHODS: Participants were drawn from the
U.S. Schizophrenia Care and Assessment Program (SCAP).
Trained assessors collected baseline data. Baseline QLS
was used (n  781; mean  56) and was modeled as a
linear function of covariates, including demographic,
clinical, medication adherence, and site variables. Pres-
ence of deficit syndrome was assigned based on proxy
methods using clinical data collected at the baseline as-
sessment (Kirkpatrick B., et al., 1993). RESULTS: Mod-
eling revealed that deficit syndrome had a negative im-
pact of 4.7 points (p  .001) on quality of life score
(range 0–120), suggesting that persons with deficit syn-
drome may experience a significantly lower quality of life
than their non-deficit counterparts, all else equal. Those
having higher hallucinations/delusions scores (p  .001)
exhibited lower QLS scores and those with higher func-
tioning scores (GAF; p  .001) exhibited higher QLS
scores. The presence of insurance other than Medicare or
Medicaid (as compared to no insurance) revealed a posi-
tive relationship to QLS score. Significance was achieved
on one site variable and indicated a negative relationship.
Weak evidence was obtained (p  .0587) indicating a
positive association between higher education level and
QLS score. CONCLUSIONS: Findings suggest that per-
sons with deficit syndrome experience lower quality of
life than those who are non-deficit. The result is expected
given the use of clinical assessment of quality of life and
is contrary to the expectation of higher self-reported
quality of life for persons with deficit. Although the clini-
cal and functional scores are significant, the impact of
deficit syndrome is at least five times greater than that of
hallucinations/delusions. The interpretation of signifi-
cance on the insurance and site variables is less clear and
may suggest that the observed variation is a result of an
unobserved mediating process, such as selection or differ-
ential access.
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OBJECTIVES: To verify whether the SF36 Mental
Health 5 item scale (MH5), an instrument commonly
used in mental health research, fulfills criteria of unidi-
mensionality and invariant measurement specified by
item response theory (IRT). METHODS: As part of a
survey of health care needs among university students in
Geneva, Switzerland, 1257 respondents (64% of eligible
persons) filled the MH5 (version 2). Each item was
scored on a 5-level frequency scale (“never” to “all of the
time”). We analyzed these data using both the traditional
method (summative scoring), and the polytomous one-
parameter IRT (or Rasch) model. RESULTS: In tradi-
tional analysis, the MH5 scale performed as expected
(single factor, Cronbach alpha 0.85, mean 67.1, standard
deviation 17.6, range 0–100). Rasch analysis revealed the
good fit of all item characteristic curves. Threshold loca-
tions for feeling “nervous” (mental health logits: 3.2,
0.7, 2.0, 3.3), “down in the dumps” (4.0, 1.7, 0.4,
1.5), “calm and peaceful” (3.0, 0.6, 0.9, 6.0), “down-
hearted and blue” (4.2, 1.6, 1.0, 3.0), and “happy”
(3.1, 0.9, 0.7, 4.2) were all ordinal, consistently with
theory, and spread widely over a span of 10.2 logits.
While classic MH5 scores and Rasch-based scores were
closely correlated (r  0.98), their relationship was
S-shaped: the intervals, in mental health logits, between
MH5 scores 0–10, 10–20, etc, up to 90–100 were: 2.23,
